England-Wales divide looms over cannabis drug - Telegraph

Cannabis-based Sativex treatment for MS set for UK approval
Sativex, a mouth spray derived from the cannabis plant, relieves muscle spasms in multiple sclerosis Photo: PA

GW Pharmaceuticals, the British company that develops cannabis-based medicines, is facing the prospect of having its multiple sclerosis treatment blocked in England but available in Wales.

The Welsh medicines board has recommended the use of Sativex to treat medium to severe muscle spasms in multiple sclerosis and is awaiting final approval from the devolved Government, The Sunday Telegraph has learnt.

Sativex could, however, be blocked from routine use in England. Draft guidelines from the National Institute of Health and Care Excellence (Nice), issued in April, recommended against the use of Sativex in multiple sclerosis. If this

...
Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/11022215/England-Wales-divide-over-cannabis-based-MS-drug-looms.html